Zydus Cadila gets USFDA’s nod to market drugs for BP, dementia

US health regulator has given its go-ahead to Zydus Cadila to market Doxazosin tablets, which are useful to treat patients with high blood pressure.


The company “has received the final approval from the United States Food and Drug Administration (USFDA) to market Doxazosin tablets USP, 1 mg, 2 mg, 4 mg, and 8 mg”, Zydus Cadila said in a statement.

The drug is used to treat high blood pressure and urinary retention associated with benign prostatic hyperplasia, it added.

The company has also received the tentative approval from the USFDA to market Lurasidone Hydrochloride Tablets in the strengths of 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg, Zydus Cadila said.


The drug is used in the treatment of schizophrenia, it added.

Both Doxazosin tablets and Lurasidone Hydrochloride tablets will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad, Zydus Cadila said.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top